Vyvgart Hytrulo

News

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

News

J&J's 'Swiss army knife' drug gets first FDA approval

Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).

News

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t

argenx's Forte acquisition delivers coeliac trial win

J&J's 'Swiss army knife' drug gets first FDA approval

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks